Perampanel is also a useful adjunctive treatment option in refractory epilepsy in children

Affiliations

Editorial

Jon Soo Kim et al. Korean J Pediatr. 2019 Jul.

. 2019 Jul;62(7):259-260.

doi: 10.3345/kjp.2019.00108. Epub 2019 Mar 5.

¹ Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Korea.

No abstract available

Conflict of interest statement

No potential conflicts of interest relevant to this article was reported.

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9. - PubMed
1. Lin KL, Lin JJ, Chou ML, Hung PC, Hsieh MY, Chou IJ, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav. 2018;85:188–94. - PubMed
1. Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, et al. Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. 2018;137:378–91. - PubMed
1. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–9. - PubMed
1. French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015;85:950–7. - PMC - PubMed